NSAIDs show ‘deleterious’ impact on fertility women with spondyloarthritis
Click Here to Manage Email Alerts
PHILADELPHIA - Among women with spondyloarthritis, those who are of older age and use of NSAIDs during preconception demonstrate longer time to conception, according to data presented at ACR Convergence 2022.
“Spondyloarthritis is one of the most common inflammatory chronic diseases, and it regularly affects women of childbearing age,” Sabrina Hamroun, MMed, of the rheumatology department at the University Hospital of Cochin, in Paris, said during a press conference at the meeting. “However, there is limited knowledge about the impact of the disease and its treatment on fertility.”
To investigate the factors impacting fertility in women with SpA, Hamroun and colleagues analyzed data from GR2, a national, multicenter cohort in France, spanning from 2015 through June 2021. Patients enrolled in the GR2 cohort during their preconception period were included in the analysis.
The primary endpoint of the analysis was the time-to-conception in patients, with secondary endpoints including the number of patients considered to be subfertile and the number of patients who were exposed to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) or biologic therapies during the preconception period.
In total, 88 of the 207 patients with SpA were included in the analysis. In all, 56 patients (63.6%) presented at follow-up with a pregnancy. Additionally, 40 patients (45.4%) were subfertile, and either did not conceive or took longer than 1 year to conceive. In this group, the average time to conception was 16.1 months, according to Hamroun.
A total of 23 (26.1%) patients were treated with NSAIDs during the preconception period, while eight (9.1%) received corticosteroids, 12 (13.6%) received conventional synthetic DMARDs and 61 (69.3%) were treated with biologics. Older age (HR = 1.22; 95% CI, 1.08-1.4) and the use of NSAIDs (HR = 3.01; 95% CI, 2.15-3.85) were associated with longer-time-to-conception.
“This study provides original results on fertility in women with SpA,” Hamroun said. “This is the first real-life description of the deleterious impacts of NSAIDs on fertility in women with SpA, and the negative impact of NSAIDs on fertility should lead us to consider their supervised discontinuation in cases of difficult conception.”
Collapse
Hamroun S. Abstract 1673. Presented at: ACR Convergence 2022; Nov. 11-14, 2022; Philadelphia (hybrid meeting).
Read more about
Click Here to Manage Email Alerts